BioStem Technologies Reports Record Second Quarter 2024 Revenue of $74.5 Million
POMPANO BEACH, Fla., Aug. 12, 2024 (GLOBE NEWSWIRE) — BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics, reports financial results for the second quarter ended June 30, 2024. The Company will host a webcast and conference call on Monday, August 12, 2024, at 4:30 pm EDT.
Related news for (BSEM)
- BioStem Technologies to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024
- BioStem Receives Institutional Review Board (IRB) Approval to Advance a Clinical Study Evaluating AmnioWrap2™ in Diabetic Foot Ulcers
- BioStem Technologies Reports Breakthrough Results with AmnioWrap2® in Retrospective Wound Care Study
- BioStem Technologies to Sponsor MRO Better Half Dash